Revisiting safety and refining benefit of rituximab–belimumab combination for refractory SLE B-cell depletion using rituximab is used to treat systemic lupus erythematosus (SLE), particularly for patients whose disease is refractory to conventional immunosuppressants (eg, mycophenolate), and ...

Just out! We challenge the prevailing caution and advocate for a biomarker-guided approach soon to be tested in the STRATIFY lupus trial: Rituximab–belimumab combination for refractory SLE @shipam.bsky.social @versusarthritis.bsky.social www.thelancet.com/journals/lan...

Thanks to @versusarthritis.bsky.social for supporting this work

@arrdept-ucldom.bsky.social
Just out! Our latest lupus paper shows IgA2⁺ B-cells & IgA2-anti-dsDNA Abs are selectively targeted
doi.org/10.1016/j.xc...
Builds on theranostic discovery doi.org/10.1016/S266...
On BEAT-Lupus doi.org/10.7326/M21-...
Lupus ≠ one-size-fits-all doi.org/10.1084/jem....

So fantastic to see this work out @shipam.bsky.social, with Prof Michael Ehrenstein and Dr Dan McCluskey. This new departmental paper shows the utility of anti-dsDNA IgA2 and IgA2+ B cells as a biomarker for response to Belimumab in SLE. Read in @cp-cell.bsky.social journal - Cell Reports Medicine.

www.nihr.ac.uk/story/strati... a big thank you to the lupus specialists and their patients who made this research possible

Simple blood test offers new hope to lupus patients Up to 69,000 people in the UK have lupus, a chronic autoimmune condition

www.independent.co.uk/news/health/...

STRATIFY lupus is a newly funded precision medicine biomarker enrichment trial funded by @versusarthritis.bsky.social and @nihr.bsky.social with support from @glaxosmithkline.bsky.social in collaboration with @shipam.bsky.social & many UK lupus specialist centres. Will start recruitment early 2026.